PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
蛋白质相关 DNA 断裂作为拓扑异构酶抑制的指标
基本信息
- 批准号:3774547
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
DNA topoisomerase I and II (top 1 and top 2) are major targets for cancer
chemotherapy. Topoisomerase poisons act by stabilizing enzyme-linked DNA
breaks which can be detected as protein-associated DNA breaks in drug-
treated cells. The goal of this project is to study drug interactions with
cellular DNA and to elucidate the antitumor mechanisms of top 1 and 2
poisons, and their selectivity for cancer cells.
We have studied the cellular effects of several new topoisomerase
inhibitors including the top 2 inhibitors, azatoxin (NCI patent) and
hydroxyrubicin, the various top 1 inhibitors presently in clinical trials,
and the dual top 1 and top 2 inhibitor, intoplicine (in early clinical
trials in Europe). Also, we have obtained evidence that top 2 poisons
differ from each other by the distribution of cleavage sites in the human
c-myc gene in the case of amsacrine and etoposides. Thus, it appears that
preferential gene damage by top 2 inhibitors may contribute to their
differential anti cancer activity.
We and others have recently described "apoptosis" as a mode of cell death,
especially in malignant hematopoietic cells exposed to topoisomerase
inhibitors. Interestingly, HL-60 cells die in interphase by apoptosis
within 3 hours after drug treatment, while human colon carcinoma HT-29
cells and Chinese hamster DC3F fibroblasts die by G2 block after 24-48
hours. We have set up an in vitro assay to reconstitute the nucleosomal
DNA fragmentation using isolated nuclei and cytoplasmic extracts and have
studied various ways to either stimulate (using protein kinase inhibitors,
such as staurosporine) or inhibit apoptosis in HL-60 cells (spermine,
Zinc, poly[ADPribose] polymerase inhibitors). Apoptosis is relevant to
cancer chemotherapy because its occurrence may explain the
hypersensitivity of leukemia to chemotherapy and drug hematological
toxicity. Hence, new approaches aimed at triggering or suppressing
apoptosis may provide new therapeutic strategies and help reduce drug side
effects.
DNA拓扑异构酶I和II(前1和前2)是癌症的主要靶点
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Y POMMIER其他文献
Y POMMIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Y POMMIER', 18)}}的其他基金
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
蛋白质相关 DNA 断裂作为拓扑异构酶抑制的指标
- 批准号:
3916548 - 财政年份:
- 资助金额:
-- - 项目类别:
TOPOISOMERASE II AS TARGET OF ACTION OF ANTICANCER DRUG
拓扑异构酶 II 作为抗癌药物的作用靶点
- 批准号:
3939497 - 财政年份:
- 资助金额:
-- - 项目类别:
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
蛋白质相关 DNA 断裂作为拓扑异构酶抑制的指标
- 批准号:
3752315 - 财政年份:
- 资助金额:
-- - 项目类别:
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
蛋白质相关 DNA 断裂作为拓扑异构酶抑制的指标
- 批准号:
3853153 - 财政年份:
- 资助金额:
-- - 项目类别:
PHARMACOLOGY OF THE HIV VIRAL DNA AND RETROVIRAL INTEGRASES
HIV 病毒 DNA 和逆转录病毒整合的药理学
- 批准号:
2463724 - 财政年份:
- 资助金额:
-- - 项目类别:
DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS
DNA拓扑异构酶作为抗癌药物的作用靶点
- 批准号:
2463710 - 财政年份:
- 资助金额:
-- - 项目类别:
DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS
DNA拓扑异构酶作为抗癌药物的作用靶点
- 批准号:
3752316 - 财政年份:
- 资助金额:
-- - 项目类别:
DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS
DNA拓扑异构酶作为抗癌药物的作用靶点
- 批准号:
3838030 - 财政年份:
- 资助金额:
-- - 项目类别:
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
蛋白质相关 DNA 断裂作为拓扑异构酶抑制的指标
- 批准号:
2463709 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Understanding and exploiting DNA topoisomerases in cancer biology
了解和利用癌症生物学中的 DNA 拓扑异构酶
- 批准号:
10296437 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Understanding and exploiting DNA topoisomerases in cancer biology
了解和利用癌症生物学中的 DNA 拓扑异构酶
- 批准号:
10473793 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Structural and mechanistic analysis of type II DNA topoisomerases
II 型 DNA 拓扑异构酶的结构和机制分析
- 批准号:
2059935 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Studentship
Conference: 2016 Gordon Research Seminar on DNA Topoisomerases to be held at Sunday River in Newry, ME on August 6-7, 2016
会议:2016 年戈登 DNA 拓扑异构酶研究研讨会将于 2016 年 8 月 6 日至 7 日在缅因州纽里的 Sunday River 举行
- 批准号:
1643077 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Standard Grant
2014 DNA Topoisomerases in Biology and Medicine Gordon Research Conference
2014 DNA 拓扑异构酶在生物学和医学戈登研究会议
- 批准号:
8714782 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Biochemical Analyses of Type II DNA Topoisomerases
II 型 DNA 拓扑异构酶的生化分析
- 批准号:
7909236 - 财政年份:2009
- 资助金额:
-- - 项目类别:
DNA Topoisomerases and DNA Topology in E. coli
大肠杆菌中的 DNA 拓扑异构酶和 DNA 拓扑
- 批准号:
0090880 - 财政年份:2001
- 资助金额:
-- - 项目类别:
Continuing Grant